These studies revealed that treatment of the CML cell line K562 with 1 uM dasatinib-based DAS-VHL PROTAC led to the degradation of more than 65% of c-ABL protein, but it was ineffective against BCR-ABL. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.